18 completed, 6 recruiting, 3 unknown, 1 active not recruiting. 11 Phase 2, 7 Phase 3, 4 Phase 4, 3 Not applicable, 3 Phase 1.
Follow Thyrotropin Alfa: new trials by email Literature Review of Thyrotropin Alfa trials Research Report on Thyrotropin Alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) Estradiol + Progesterone, Ovitrelle ( Hcg 250 mcg) - Infertilities, Embryo Transfer | Phase 4 | Recruiting | Fundacion Clinic per a la Recerca Biomédica | 334 | 2025-02-01 | 2025-04-02 |
| Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation Biospecimen Collection, Cobimetinib, Computed Tomography - Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 21 | 2024-07-15 | 2026-02-02 |
| Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer Recombinant Human Thyroid Stimulating Hormone - Recombinant Human Thyroid Stimulating Hormone | Not applicable | Recruiting | Nanjing First Hospital, Nanjing Medical University | 15 | 2024-06-30 | 2024-05-28 |
| Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment Recombinant Human Thyroid Stimulating Hormone - DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C | Not applicable | Recruiting | Nanjing First Hospital, Nanjing Medical University | 30 | 2024-04-20 | 2024-05-08 |
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Selpercatinib, Sodium Iodine I-131, rhTSH - Thyroid Cancer, Thyroid Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2023-03-01 | 2024-12-12 |
| rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC) rhTSH, Radioiodine (131I) - Differentiated Thyroid Cancer | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 390 | 2021-10-06 | 2026-09-08 |
| Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal rhTSH - Differentiated Thyroid Cancer | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 201 | 2021-09-10 | 2024-03-28 |
| rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid Cancer Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH), radioactive iodine - Differentiated Thyroid Cancer | Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 123 | 2020-11-23 | 2026-09-04 |
| The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer Thyrogen, I-131, I-124 - Thyroid Cancer | Phase 2 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 30 | 2019-07-29 | 2026-09-09 |
| Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients Recombinant Human Thyroid Stimulating Hormone for Injection - Differentiated Thyroid Cancer | Phase 1 / Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 64 | 2019-06-10 | 2024-03-06 |
| Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome Pregnyl (1,500) IU, 1.5 mL of normal saline - Ovarian Hyperstimulation Syndrome, Infertility, Female | Phase 4 | Unknown | Mount Sinai Hospital, Canada | 80 | 2019-05-01 | 2023-07-03 |
| Follicle Size and Oocyte Development Follicle measurment, Ovitrelle ( Hcg 250 mcg), Decapeptyl ( GnRH Agonist 0.1 mg*2 ) - IVF Treatment | Not applicable | Completed | Sheba Medical Center | 200 | 2018-07-01 | 2022-06-24 |
| Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer Trametinib, Dabrafenib, 131I - Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation | Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 40 | 2017-12-27 | 2026-03-23 |
| Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients Period 1 GX-30, Period 2 THYROGEN®, Period 1 THYROGEN®, Period 2 GX-30 - Total Thyroidectomy, Near-total Thyroidectomy | Phase 1 / Phase 2 | Completed | Genexine, Inc. | 8 | 2017-09-07 | 2020-09-09 |
| Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Vemurafenib, serial 124I PET/CT, thyrotropin alpha - Thyroid Carcinoma | Early Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 12 | 2014-05-20 | 2025-06-18 |
| Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? rhTSH stimulation, I131, Follow up - Low Risk Differentiated Thyroid Cancer | Phase 3 | Active not recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 776 | 2013-05-13 | 2023-05-17 |
| Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 rhTSH - Differentiated Thyroid Cancer | Phase 1 | Completed | University of Colorado, Denver | 5 | 2012-11-30 | 2019-10-24 |
| A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours Thyrogen, 131I, Thyroid Hormone Withdrawal - Thyroid Cancer | Completed | Genzyme, a Sanofi Company | 144 | 2012-05-01 | 2015-03-23 | |
| Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer rhTSH - Thyroid Cancer | Phase 4 | Completed | Copenhagen University Hospital at Herlev | 56 | 2008-02-01 | 2013-01-10 |
| Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients Thyrogen, thyroid hormone withdrawal, iode 131 - Thyroid Cancer | Phase 3 | Unknown | Gustave Roussy, Cancer Campus, Grand Paris | 950 | 2007-02-01 | 2007-02-19 |
Showing 20 of 28. Sign in to see all of them.
Thyroid Neoplasms (12) · Adenocarcinoma, Follicular (5) · Thyroid Cancer, Papillary (5) · Goiter, Nodular (1) · Graves Disease (1) · Head and Neck Neoplasms (1) · Heterotaxy Syndrome (1) · Hypothyroidism (1) · Infertility, Female (1) · Neoplasm Metastasis (1) · Ovarian Hyperstimulation Syndrome (1) · Patient Satisfaction (1)
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (4) · Genzyme, a Sanofi Company (3) · Gustave Roussy, Cancer Campus, Grand Paris (3) · Nanjing First Hospital, Nanjing Medical University (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · City of Hope Medical Center (1) · Copenhagen University Hospital at Herlev (1) · Fundacion Clinic per a la Recerca Biomédica (1) · Genexine, Inc. (1) · Johns Hopkins University (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Mount Sinai Hospital, Canada (1) · National Cancer Institute (NCI) (1) · Odense University Hospital (1)
United States (9) · China (6) · France (5) · Denmark (3) · Canada (2) · Germany (2) · Italy (2) · Spain (2) · Israel (1) · Portugal (1) · South Korea (1) · United Kingdom (1)
Yansong Lin, PhD (3) · Alan L. Ho, MD, PhD (1) · Birte Nygaard, Md, PhD (1) · Feng Wang (1) · Jennifer Kwak, MD (1) · Joanna Klubo-Gwiezdzinska, M.D. (1) · Lori J. Wirth, MD (1) · Miguel Russo, MD (1) · Mu Il Kang, M.D., Ph. D. (1) · Paul W Ladenson, MD (1) · Sasan Fazeli (1) · Steen J. Bonnema, MD (1) · Steven Sherman (1)
PMID 16384850, PMID 16864757, PMID 18249377, PMID 19158200, PMID 19850694, PMID 20519346, PMID 22551127, PMID 22551128, PMID 27448022, PMID 29807824, PMID 30256977, PMID 30501974, PMID 34961921, PMID 35263518, PMID 37350119, PMID 39586309, PMID 40488858, PMID 41861727, PMID 7521343, PMID 8841223, PMID 9740448
2005 (1), 2017 (1), N01CM62207 (1), P30CA016672 (1), P30CA033572 (1)